<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240379</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.146</org_study_id>
    <secondary_id>2019-A01278-49</secondary_id>
    <nct_id>NCT04240379</nct_id>
  </id_info>
  <brief_title>Metacognition Assessment in Patient With Multiple Sclerosis</brief_title>
  <acronym>METACOGSEP</acronym>
  <official_title>Metacognition Assessment in Patient With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Grenoble Alps</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assessed the level of consciousness of MS patients suffering of cognitive and
      motor disorders. Understanding the awareness of the disease is crucial to allow better
      management of these patients. It has been shown, for other neurological pathologies, that a
      lack of awareness of deficits leads to inefficient rehabilitation and a disorder of
      understanding the impact of deficits in daily activities. Metacognition could be altered with
      age, so we will include participants between 18 and 60 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject who have to do neurological assessement by the Multiple sclerosis Functional
      Composite (MSFC) will be enrolled.

      The patient will estimate the time to undergo the test. This time will be compared to the
      time really make by the patient to realise test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metacognitive precision</measure>
    <time_frame>Day 1</time_frame>
    <description>Metacognitive precision based on Multiple Sclerosis Functional Composite (MSFC) score</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be proposed to subject :

          -  Male or female with diagnosis of MS,

          -  admitted in neurological unit for passing the MSFC (Multiple Sclerosis Functionnal
             Composite) test

          -  who respect selection criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple sclerosis

          -  Voluntary for participate to study

        Exclusion Criteria:

          -  Neurological disease other than Multiple Sclerosis

          -  psychiatric disease, other than depressiveness

          -  illicit substance abuse

          -  Persons referred to in Articles L1121-5 to 8 of the French Public Health Code
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Audrey MAZANCIEUX, PhD</last_name>
    <phone>33 6 41 99 61 52</phone>
    <email>audrey.mazancieux@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier CASEZ, MD</last_name>
    <phone>33 4 76 76 58 71</phone>
    <email>OCasez@chu-grenbole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey MAZANCIEUX</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CASSEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Calabrese P. Neuropsychology of multiple sclerosis--an overview. J Neurol. 2006 Feb;253 Suppl 1:I10-5. Review.</citation>
    <PMID>16477479</PMID>
  </reference>
  <reference>
    <citation>Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008 Dec;7(12):1139-51. doi: 10.1016/S1474-4422(08)70259-X. Review.</citation>
    <PMID>19007738</PMID>
  </reference>
  <results_reference>
    <citation>Beatty WW, Monson N. Metamemory in multiple sclerosis. J Clin Exp Neuropsychol. 1991 Mar;13(2):309-27.</citation>
    <PMID>1688342</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Multiple Sclerosis Functional Composite (MSFC)</keyword>
  <keyword>Metacognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

